Minimal Manipulation Under 21 CFR Part 1271 — Regulatory Standard
Minimal manipulation is a core regulatory criterion used by the U.S. Food and Drug Administration (FDA) when evaluating Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps).
This criterion is defined in 21 CFR 1271.3(f) and must be evaluated within the broader framework established under 21 CFR Part 1271.
Regulatory classification criteria are further defined under 21 CFR 1271.10(a) .
Minimal manipulation is one of several requirements used to determine whether a product may qualify for regulation solely under Section 361 of the Public Health Service Act.
Documentation and Regulatory Education
Licensed medical professionals and organizations may request educational materials related to regulatory criteria, donor eligibility standards, and documentation practices referenced within this resource.
These materials are intended to support informed evaluation of regulatory frameworks and sourcing transparency.
Regulatory Definition
- Structural tissue: Processing that does not alter the original relevant characteristics relating to its utility for support, covering, or structural function.
- Cells or nonstructural tissues: Processing that does not alter relevant biological characteristics.
Structural Tissue Considerations
- Support and cushioning
- Barrier or covering function
- Connective structure
Cellular and Nonstructural Tissue Considerations
- Biological activity
- Metabolic characteristics
- Cellular function
Role in Regulatory Classification
- Minimal manipulation
- Homologous use
- Combination limitations
- Systemic effect considerations
For applied interpretation examples: Homologous use interpretation →
Regulatory Notice
This information is for educational purposes only.
Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
For use by licensed medical professionals.